Глава 14. Саркоидоз

Körber M., Kamp S., Kothe H. et al. Pentoxifylline inhibits secretion of O2- and TNF-alpha by alveolar macrophages in patients with sarcoidosis // Immun. Infekt. 1995. Vol. 23. N. 3. P. 107–110.

Landi C., Carleo A., Cillis G., Rottoli P. Sarcoidosis: proteomics and new perspectives for improving personalized medicine // Expert Rev. Proteomics. 2018. Vol. 15. N. 10. P. 829–835. DOI: https://doi.org/10.1080/14789450.2018.1528148.

Lentz R.J., Argento A.C., Colby T.V. et al. Transbronchial cryobiopsy for diffuse parenchymal lung disease: a state-of-the-art review of procedural techniques, current evidence, and future challenges // J. Thorac. Dis. 2017. Vol. 9. N. 7. P. 2186–2203. DOI: https://doi.org/10.21037/jtd.2017.06.96.

Lewis S.J., Ainslie G.M., Bateman E.D. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis // Sarcoidosis Vasc. Diffuse Lung Dis. 1999. Vol. 16. P. 87–92.

Löffler C., Bergner R. Sarcoidosis: renal manifestations // Z. Rheumatol. 2017. Vol. 76. N. 5. P. 398–407. DOI: https://doi.org/10.1007/s00393-017-0301-9.

Madan K., Dhungana A., Mohan A. et al. Conventional transbronchial needle aspiration versus endobronchial ultrasound-guided transbronchial needle aspiration, with or without rapid on-site evaluation, for the diagnosis of sarcoidosis: a randomized controlled trial // J. Bronchology Interv. Pulmonol. 2017. Vol. 24. N. 1. P. 48–58.

Madaule S., Lauque D., Sailler L. et al. Splenomegaly in sarcoidosis: clinical features and outcome. Analysis of 17 cases // Rev. Med. Interne. 2004. Vol. 25. N. 5. P. 348–356.

Majjad A., Bezza A., Biyi A. et al. Pulmonary sarcoidosis following etanercept treatment for ankylosing spondylitis: a case report and review of the literature // Case Rep. Rheumatol. 2018. Vol. 2018. Article ID 9867248. DOI: https://doi.org/10.1155/2018/9867248.

Marchetti M., Baker M.G., Noland M.M. Treatment of subcutaneous sarcoidosis with hydroxychloroquine: report of 2 cases // Dermatol. Online J. 2014. Vol. 20. N. 1. Article ID 21250.

Matsou A., Tsaousis K.T. Management of chronic ocular sarcoidosis: challenges and solutions // Clin. Ophthalmol. 2018. Vol. 12. P. 519–532. DOI: https://doi.org/10.2147/OPTH.S128949.

Morimoto T., Azuma A., Abe S. et al. Epidemiology of sarcoidosis in Japan // Eur. Respir. J. 2008. Vol. 31. N. 2. P. 372–379.

Niedoszytko P. Rehabilitation of patients with sarcoidosis // Pol. Merkur. Lekarski. 2018. Vol. 44. N. 261. P. 150–151.

Paramothayan N., Lasserson T., Jones P. Corticosteroids for pulmonary sarcoidosis // Cochrane Database Syst. Rev. 2005. Vol. 2. CD001114.

Parikh K.S., Dahhan T., Nicholl L. et al. Clinical features and outcomes of patients with sarcoidosis-associated pulmonary hypertension // Sci. Rep. 2019. Vol. 9. N. 1. P. 4061. DOI: https://doi.org/10.1038/s41598-019-40030-w.

Park M.K., Fontana Jr, Babaali H. et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis // Sarcoidosis Vasc. Diffuse Lung Dis. 2009. Vol. 26. N. 2. P. 121–131.

Patterson K.C., Chen E.S. The pathogenesis of pulmonary sarcoidosis and implications for treatment // Chest. 2018. Vol. 153. N. 6. P. 1432–1442. DOI: https://doi.org/10.1016/j.chest.2017.11.030.

Popova E.N., Bolevich S.B., Fomin V.V. et al. Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite) // Eur. Respir. J. 2006. Vol. 28. Suppl. 50. Ref. P2491.

Rabinowitz M.P., Murchison A.P. Orbital sarcoidosis treated with hydroxychloroquine // Orbit. 2011. Vol. 30. N. 1. P. 13–15. DOI: https://doi.org/10.3109/01676830.2010.524268.

Raj R., Nugent K. Leflunomide-induced interstitial lung disease (a systematic review) // Sarcoidosis Vasc. Diffuse Lung Dis. 2013. Vol. 30. N. 3. P. 167–176.

Refiskaya N.V., Stepanenko T.A., Jablonskiy P.K., Baranova O.P. The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis // Eur. Respir. J. 2006. Vol. 28. Suppl. 50. Ref. E3134.

Rosenthal D.G., Anderson M.E., Petek B.J. et al. Invasive hemodynamics and rejection rates in patients with cardiac sarcoidosis after heart transplantation // Can. J. Cardiol. 2018. Vol. 34. N. 8. P. 978–982. DOI: https://doi.org/10.1016/j.cjca.2018.03.021.

Ruža I., Lucāne Z. Serum and urinary calcium level in Latvian patients with sarcoidosis // Reumatologia. 2018. Vol. 56. N. 6. P. 377–381. DOI: https://doi.org/10.5114/reum.2018.80715.

Sahoo D.H., Bandyopadhyay D., Xu M. et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis // Eur. Respir. J. 2011. Vol. 38. N. 5. P. 1145–1150. DOI: https://doi.org/10.1183/09031936.00195010.

Sahu P., Sharma S., Sharma N., Sharma S., Garg S. Unusual clinical presentations in early-onset childhood sarcoidosis: a correlation or coincidence? // J. Clin. Diagn. Res. 2017. Vol. 11. N. 8. P. WD01–WD03. DOI: https://doi.org/10.7860/JCDR/2017/27841.10389.

Salamo O., Roghaee S., Schweitzer M.D. et al. White donor, younger donor and double lung transplant are associated with better survival in sarcoidosis patients // Sci. Rep. 2018. Vol. 8. N. 1. P. 6968. DOI: https://doi.org/10.1038/s41598-018-25144-x.

Scherholz M.L., Schlesinger N., Androulakis I.P. Chronopharmacology of glucocorticoids // Adv. Drug Deliv. Rev. 2019. Vol. 151–152. P. 245–261. DOI: https://doi.org/10.1016/j.addr.2019.02.004. Epub 2019 Feb 21.

Sorabjee J.S., Garje R. Reactivation of old scars: inevitably sarcoid // Postgrad. Med. J. 2005. Vol. 81. N. 951. P. 60–61.

Stern B.J., Royal W. 3rd, Gelfand J.M. et al. Definition consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis Consortium Consensus Group // JAMA Neurol. 2018. Vol. 75. N. 12. P. 1546–1553. DOI: https://doi.org/10.1001/jamaneurol.2018.2295.

Suzuki T., Tsushima K., Kawata N. et al. Estimation using the impulse oscillation system in patients with pulmonary sarcoidosis // Sarcoidosis Vasc. Diffuse Lung Dis. 2015. Vol. 32. N. 2. P. 144–150.

Taimeh Z., Hertz M.I., Shumway S., Pritzker M. Lung transplantation for pulmonary sarcoidosis. Twenty-five years of experience in the USA // Thorax. 2016. Vol. 71. N. 4. P. 378–379. DOI: https://doi.org/10.1136/thoraxjnl-2015-207497.

Tejera Segura B., Holgado S., Mateo L. et al. Löfgren syndrome: a study of 80 cases // Med. Clin. (Barc.). 2014. Vol. 143. N. 4. P. 166–169. DOI: https://doi.org/10.1016/j.medcli.2014.02.029.

Terwiel M., van Moorsel C.H.M. Clinical epidemiology of familial sarcoidosis: a systematic literature review // Respir. Med. 2019. Vol. 149. P. 36–41. DOI: https://doi.org/10.1016/j.rmed.2018.11.022.

Thomeer M., Demedts M., Vandeurzen K. et al. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders // Acta Clin. Belg. 2001. Vol. 56. N. 3. P. 163–172.

Ungprasert P., Matteson E.L. Neurosarcoidosis // Rheum. Dis. Clin. North Am. 2017. Vol. 43. N. 4. P. 593–606. DOI: https://doi.org/10.1016/j.rdc.2017.06.008. Epub 2017 Aug 23.

Utz J.P., Limper A.H., Kalra S. et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis // Chest. 2003. Vol. 124. N. 1. P. 177–185.

Van Dee L., Stehouwer M., van Bemmel T. Systemic sarcoidosis associated with exposure to Borrelia burgdorferi in a 21-year-old man // Eur. J. Case. Rep. Intern. Med. 2018. Vol. 5. N. 10. Article ID 000942. DOI: https://doi.org/10.12890/2018_000942.

Van Schalkwyk E.M., Bezuidenhout J., Wyser C.P. et al. Comparison of bronchoalveolar lavage, open lung biopsy and lung function in sarcoidosis // Eur. Respir. J. 1997. Vol. 10. Suppl. 25. Ref. 1357. P. 206s.

Vorselaars A.D., Cremers J.P., Grutters J.C., Drent M. Cytotoxic agents in sarcoidosis: which one should we choose? // Curr. Opin. Pulm. Med. 2014. Vol. 20. N. 5. P. 479–487.

Wanat K.A., Rosenbach M. Cutaneous sarcoidosis // Clin. Chest Med. 2015. Vol. 36. N. 4. P. 685–702.

Wells A.U., Hirani N.; and on behalf of the British Thoracic Society Interstitial Lung. Interstitial lung disease guideline: the British and the Irish Thoracic Society of Australia and New Zealand Thoracic Society in collaboration with the Thoracic Society of Australia and Disease Guideline Group, a subgroup of the British Thoracic Society Standards // Thorax. 2008. Vol. 63. P. v1–v58.

Yablonsky P., Kusnetsov I., Pishchik V. et al. Differential diagnosis of mediastinal lymphoadenopathy // Eur. Respir. J. 2000. Vol. 16. Suppl. 31. Ref. 5731.

Zabel P., Entzian P., Dalhoff K., Schlaak M. Pentoxifylline in treatment of sarcoidosis // Am. J. Respir. Crit. Care Med. 1997. Vol. 155. N. 5. P. 1665–1669.

Zhao M.M., Du S.S., Li Q.H. et al. High throughput 16SrRNA gene sequencing reveals the correlation between Propionibacterium acnes and sarcoidosis // Respir. Res. 2017. Vol. 18. N. 1. P. 28. DOI: https://doi.org/10.1186/s12931-017-0515-z.